NeOnc Insider Buying Expands Ahead of FDA Discussions and Two Key Brain Cancer Data Presentations
Insiders continue to Buy NeOnc (NASDAQ: NTHI) as it heads into a potentially important period for its clinical programs and FDA meetings
Insiders continue to Buy NeOnc (NASDAQ: NTHI) as it heads into a potentially important period for its clinical programs and FDA meetings